FY2025 · period end Dec '25 · from the 10-K filed Feb 27, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $3.95B | $2.70B | $1.82B | $1.43B | $1.17B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $0.01B | negative: -$0.10B | negative: -$0.13B | negative: -$0.13B | negative: -$0.18B |
| Net Income | negative: -$0.00B | negative: -$0.13B | negative: -$0.15B | negative: -$0.15B | negative: -$0.20B |
| EPS (Diluted) | $0.00 | negative: -$0.67 | negative: -$0.79 | negative: -$0.83 | negative: -$1.14 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $1.07B | $0.78B | $0.59B | $0.63B | $0.63B |
| Total Liabilities | $0.89B | $0.68B | $0.43B | $0.39B | $0.32B |
| Stockholders' Equity | $0.18B | $0.10B | $0.16B | $0.24B | $0.31B |
| Cash & Equivalents | $0.58B | $0.43B | $0.20B | $0.41B | $0.47B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.14B | $0.03B | negative: -$0.06B | negative: -$0.05B | negative: -$0.08B |
| Capital Expenditures | $0.03B | $0.04B | $0.04B | $0.02B | — |
| Free Cash Flow | $0.11B | negative: -$0.01B | negative: -$0.10B | negative: -$0.07B | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | negative: -0.0% | negative: -0.0% | negative: -0.1% | negative: -0.1% | negative: -0.2% |
| Net Margin | negative: -0.0% | negative: -0.0% | negative: -0.1% | negative: -0.1% | negative: -0.2% |
| Return on Equity | negative: -0.5% | negative: -98.9% | negative: -74.5% | negative: -54.8% | negative: -116.0% |
| Return on Assets | negative: -0.1% | negative: -18.6% | negative: -24.2% | negative: -23.6% | negative: -40.3% |
| Debt / Equity | 1.80× | 3.18× | 1.02× | 0.67× | 0.49× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001628280-26-051060 | Jun 30, 2026 | Jul 30, 2026 | Jul 30, 2026 20:14 UTC | EDGAR |
| 8-K | 0001171843-26-005078 | Jul 30, 2026 | Jul 30, 2026 | Jul 30, 2026 20:01 UTC | EDGAR |
| 8-K | 0001628280-26-041926 | Jun 4, 2026 | Jun 9, 2026 | Jun 9, 2026 20:31 UTC | EDGAR |
| 8-K | 0001628280-26-034147 | May 6, 2026 | May 12, 2026 | May 12, 2026 20:33 UTC | EDGAR |
| 10-Q | 0001628280-26-028901 | Mar 31, 2026 | Apr 30, 2026 | Apr 30, 2026 20:14 UTC | EDGAR |
| 8-K | 0001171843-26-002895 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 20:01 UTC | EDGAR |
| 8-K | 0001193125-26-091486 | Mar 2, 2026 | Mar 4, 2026 | Mar 4, 2026 21:08 UTC | EDGAR |
| 10-K | 0001628280-26-012545 | Dec 31, 2025 | Feb 27, 2026 | Feb 27, 2026 02:18 UTC | EDGAR |
Direct links to SEC EDGAR. ALHC has additional filings available on the SEC site.
6 numbers Alignment Healthcare, Inc. later changed — same XBRL tag, both filings linked.
Other Nonoperating Income (Expense)·Q1 2024
Major restatementwas-$5.5M
Revised up in a 10-Q.
Other Nonoperating Income (Expense)·FY 2022
Major restatementwas-$20.7M
Revised up in a 10-K.
Deferred Tax Assets, Other·As of Dec 31, 2024
Major restatementwas$5.8M
Revised down in a 10-K.
Operating Lease, Cost·FY 2023
Major restatementwas$2.3M
Revised up in a 10-K.
Operating Lease, Cost·FY 2022
Major restatementwas$2.8M
Revised up in a 10-K.
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest·FY 2025
Notable restatementwas-$978K
Revised down.
ALHC is not the only one.
See every restatement we've found across the market — or get an alert the next time ALHC revises a number.
Restatements are detected by comparing every vintage of a fact across all of Alignment Healthcare, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ALHC's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Alignment Healthcare, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ALHC yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ALHC and publish the result to your public profile.
Ask about Alignment Healthcare, Inc.
Continue in Workspace — cited answers on ALHC, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs